Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01027234 · ClinicalTrials.gov registry record · Phase 1

This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses

A Phase 1 study, sponsored by AstraZeneca.

Terminated
Registry status
Phase 1
Development phase
40
Enrollment target

NCT01027234 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01027234, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.

TERMINATED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

The main purpose of this study is to assess the safety and tolerability of AZD8418 after single increasing oral doses. Another purpose of this study is to evaluate the pharmacokinetics (also called PK - how the study drug enters and leaves the body and how your body acts on the study drug) of AZD8418. Part B of the study will assess the effect of food on the safety and pharmacokinetics of AZD8418.

Interventions

  • DRUG Placebo
  • DRUG AZD8418

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2009-11
Est. Completion 2010-03
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT01027234

The ClinicalTrials.gov registry entry for NCT01027234 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01027234 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01027234 about?

NCT01027234 is a clinical study titled "This Study Will Assess the Safety and Tolerability of AZD8418 After Single Increasing Oral Doses". The main purpose of this study is to assess the safety and tolerability of AZD8418 after single increasing oral doses. Another purpose of this study is to evaluate the pharmacokinetics (also called PK - how the study drug enters and leaves the body and how your body acts on the study drug) of AZD84...

What is the current status of trial NCT01027234?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2009-11. Estimated completion is 2010-03.

What interventions are being tested in trial NCT01027234?

The interventions under investigation include: Placebo (DRUG), AZD8418 (DRUG).

Who is sponsoring clinical trial NCT01027234?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.